Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)

Summary

There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. * Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group. * Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment). * Safety comparison: Safety verification by identifying major side effects in the HCQ group."

Timeline

Start

2020-04-01

Primary completion

2020-06-29

Completion

2020-06-29

Outcome

Outcome not reported

Stopped (Enrollment): “No Participants Enrolled”

Drugs

Indications

No indication recorded.